HOTH News and Press, Hoth Therapeutics Inc. From 08/21/19

Hoth Therapeutics (NASDAQ: HOTH ) inks an agreement with Greenville, SC-based Zylö Therapeutics to develop an new topical therapy for cutaneous lupus erythematosus  (CLE), an autoimmune disorder affecting the skin. More news on: Hoth Therapeutics, Inc., Healthcare stocks new...

NEW YORK , Aug. 21, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis to chronic wound disorders, today announced it...

The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) was in the red again last week, falling from 3,283.64 points on Monday’s (July 22) open to 3,283.82 points as of 1:58 p.m. EDT on Friday (July 26). On Thursday (July 25),  news hit that the US Food and Drug Administration (FDA) ...

Gainers : Therapix Biosciences (NASDAQ: TRPX ) +45% . Chiasma (NASDAQ: CHMA ) +31% . Achillion Pharmaceuticals (NASDAQ: ACHN ) +24% . Hoth Therapeutics (NASDAQ: HOTH ) +20% . Torchlight Energy Resources (NASDAQ: TRCH ) +17% . Realogy Holdings (NYSE: RLGY ) +16% . ClearSign Combustion...

Ultra-thinly traded nano cap Hoth Therapeutics ( HOTH ) is up  9% , albeit on only 369 shares, on the heels of positive results from a pilot study of BioLexa for patients with diabetic skin ulcers. More news on: Hoth Therapeutics, Inc., Healthcare stocks news, Stocks on the move, ...

July 22, 2019 Palm Beach, FL – July 22, 2019 –  According to a report from Grand View Research, the global diabetic foot ulcer treatment market size is expected to reach a value of USD 6.82 billion by 2025, according to a new report by Grand View Research, I...

NEW YORK , July 22, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well...

Hoth Therapeutics (NASDAQ: HOTH ) has entered into an exclusive license option agreement with the George Washington University (GW) pertaining to its intellectual property on the use of Aprepitant in treating skin-related and other side effects from drugs used to treat cancer. More news ...

NEW YORK , July 15, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and...

June 27, 2019 Palm Beach, FL – June 27, 2019 –  In today’s medical and financial environments, defending against risks is essential. In the financial world, financial planning can protect against most risks… in the medical world however, it is the ...